New drug for breast cancer patients to 'significantly improve the treatment options'

Patients in Ireland could benefit from a potentially life-saving new clinical trial to treat it.

New drug for breast cancer patients to 'significantly improve the treatment options'

Help could be on the way for women with aggressive breast cancer.

Patients in Ireland could benefit from a potentially life-saving new clinical trial to treat it, according to the Averil Power.

The Irish Cancer Society is asking people across the country to support Daffodil Day today so it can fund more research.

Chief executive Ms Power says a UCD researcher has made the new treatment discovery:

"One of the researchers that we support, Dr Antoinette Perry in UCD, has discovered a new drug that has the potential to significantly improve the treatment options for women with a particularly aggressive form of breast cancer," she revealed.

"She's hoping to open a clinical trial later in the year where Irish women will be the first in the world to get access to it.

"This has the potential to massively transform the treatment options for these women."

more courts articles

Man admits killing Irish pensioner (87) on mobility scooter in London Man admits killing Irish pensioner (87) on mobility scooter in London
Former DUP leader Jeffrey Donaldson arrives at court to face sex charges Former DUP leader Jeffrey Donaldson arrives at court to face sex charges
Case against Jeffrey Donaldson to be heard in court Case against Jeffrey Donaldson to be heard in court

More in this section

Stardust nightclub fire Tánaiste: Government plan to commemorate Stardust tragedy under way 
Irish mum prepares for court battle in Cairo to get her children back from their father Irish mum prepares for court battle in Cairo to get her children back from their father
Entries for BT Young Scientist exhibition open three months early Entries for BT Young Scientist exhibition open three months early
War_map
Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited